The neuronal nitric oxide synthase C-terminal antiserum was quality control tested using standard immunohistochemical methods. The antiserum demonstrates strongly positive labeling of rat hypothalamus, striatum, cortex and spinal cord using indirect immunofluorescent and biotin/avidin-HRP techniques. Recommended primary dilutions are 1/1,000 - 1/1,500 in PBS/0.3% Triton X-100 - Cy3 Technique and 1/8,000 - 1/12,000 in PBS/0.3% Triton X-100 - Bn/Av-HRP Technique. By Western blot analysis of brain homogenates the antibody specifically labels a band of approximately 155 kD. Immuno-labeling is completely abolished by pre-adsorption with synthetic human nNOS (1419-1433) at 5 µg per mL of diluted antibody. No cross reactivity with other forms of NOS were observed. The nNOS antiserum has been used successfully in human, rat, mouse, guinea pig, cat, and monkey tissue. Detection of nNOS from other species will depend upon sequence homology.
The peptide control for Neurokinin 1 Receptor is intended for the immuno-adsorption of Neurokinin 1 Receptor antiserum, catalog number 20060. Pre-adsorption of Neurokinin 1 Receptor antiserum, diluted according to the antibody specification sheet, with 10 µg/mL NK1R peptide immunogen following the instructions below provides complete blockage of Neurokinin 1 Receptor immunolabeling.
The peptide control for Neurokinin 1 Receptor is intended for the immuno-adsorption of Neurokinin 1 Receptor antiserum, catalog number 20060. Pre-adsorption of Neurokinin 1 Receptor antiserum, diluted according to the antibody specification sheet, with 10 µg/mL NK1R peptide immunogen following the instructions below provides complete blockage of Neurokinin 1 Receptor immunolabeling. The peptide is provided as 100 µL of 50 mg of synthetic peptide corresponding to rat NK1R 393-407.
The peptide control for C-FOS is intended for the immuno-adsorption of C-FOS antiserum, catalog number 26209. Pre-adsorption of C-FOS antiserum, diluted according to the antibody specification sheet, with 5ug/ml C-FOS peptide immunogen following the instructions below provides complete blockage of C-FOS immunolabeling. The peptide is provided as 25ug of lyophilized human C-FOS, and approximately 0.09% sodium azide, sequence 4-17. Please read the instructions carefully.
The peptide control for nNOS (C-terminal) is intended for the immuno-adsorption of nNOS (C-terminal) antiserum, catalog number 24287. Pre-adsorption of nNOS (C-terminal) antiserum, diluted according to the antibody specification sheet, with 5 µg/ml nNOS peptide immunogen following the instructions below provides complete blockage of nNOS (C-terminal) immunolabeling. The peptide is provided as 25 µg of lyophilized human nNOS, sequence 1419-1433. Please read the instructions carefully before beginning the procedure.
Pre-adsorption of Mu Opioid Receptor antiserum, diluted according to the antibody specification sheet, with 10 µg/ml Mu Opioid Receptor peptide immunogen following the instructions below provides complete blockage of Mu Opioid Receptor immunolabeling.
The ImmunoStar peptide control for 5-HT2A Receptor is intended for the immuno-adsorption of 5-HT2A Receptor antiserum, catalog number 24288. Pre-adsorption of 5-HT2A Receptor antiserum, diluted according to the antibody specification sheet, with 5 µg/ml 5-HT2A Receptor peptide immunogen following the instructions below provides complete blockage of 5-HT2A Receptor immunolabeling. The peptide is provided as 25 µg of lyophilized rat 5-HT2A Receptor, sequence 22-41. Also, this antiserum contains 0.09% sodium azide. Please read the instructions carefully before beginning the procedure.
The peptide control for 5-HT Transporter is intended for the immuno-adsorption of 5-HT Transporter antiserum, catalog number 24330. Pre-adsorption of 5-HT Transporter antiserum, diluted according to the antibody specification sheet, with 5 µg/ml 5-HT Transporter peptide immunogen following the instructions below provides complete blockage of 5-HT Transporter immunolabeling. The peptide is provided as 25 µg of lyophilized rat 5-HT Transporter, sequence 602-622. Please read the instructions carefully before beginning the procedure.
The 5-HT Transporter Peptide Control: rat 5-HT Transporter, sequence 579-599. Pre-adsorption of 5-HT Transporter antiserum, diluted according to the antibody specification sheet, with 5 µg/ml 5-HT Transporter peptide immunogen following the instructions below provides complete blockage of 5-HT Transporter immunolabeling. The peptide is provided as 25 µg of lyophilized rat 5-HT Transporter, sequence 602-622.
The 5-HT Transporter was raised to a synthetic peptide corresponding to amino acids 579-599 of rat 5HT transporter coupled to KLH. The ImmunoStar serotonin (5HT) transporter was quality control tested using standard immunohistochemical methods. The antiserum demonstrates strongly positive labeling of rat raphe nuclei, hypothalamus, cortex and spinal cord using indirect immunofluorescent and biotin/avidin-HRP techniques. Recommended primary dilutions for these methods are 1/800 - 1/1,000 in PBS/0.3% Triton X-100 - Cy3 and 1/10,000 - 1/15,000 in PBS/0.3% Triton X-100 - Biotin/avidin-HRP. By Western blot analysis using rat brain extracts of cortex, hypothalamus, midbrain, and hindbrain, the antibody specifically labels a single band. Immunolabeling is completely abolished by pre-adsorption with synthetic rat 5HT transporter (602-622).
The antibody produces strong labeling of VAChT at dilutions of 1/200 - 1/400 using indirect immunofluorescence and at dilutions of 1/3,000 - 1/5,000 using biotin-streptavidin/HRP technique in rat basal forebrain.
Product Type:
Antibody - Antibodies
Antibody Type:
polyclonal
Format:
Lyophilised
Host Animal:
Goat
Species Reactivity:
Human, Mouse, Rat
Immunogen:
Rat VAChT 511-530
Applications:
Electron Microscopy; Immunocytochemistry; Immunofluorescence; Immunohistochemistry.
Solute carrier family 18, member 3;solute carrier family 18 (vesicular monoamine) member 3; solute carrier family 18 (vesicular acetylcholine), member 3;rVAT; VACht
Additional Info:
The VAT Antibody produces strong labeling of VAChT at a dilution of 1/3,000 - 1/5,000 using biotin-streptavidin/HRP technique in rat basal forebrain.
Gene Symbol:
Slc18a3,60422
NCBI Gene Aliases:
Solute carrier family 18, member 3; member 3;rVAT; VACht
The 5-HIAA antibody was raised to 5-HIAA coupled to BSA with paraformaldehyde. The antibody produces moderate labeling of raphe neurons in normal rat. In rats whose serotonergic system has been activated, staining intensity is increased to a maximum label. Recommended dilutions of the antiserum are 1/200-1/400 for indirect immunofluorescence and 1/4000-1/8000 for biotin-streptavidin/HRP technique. The specificity of the antiserum was evaluated using a model system of gelatin-indole plugs by a method similar to published procedures (Schipper and Tilders, 1983). Results showed that the 5-HIAA antibody dose dependently stained 5-HIAA but did not stain any concentration of 5-HT or 5-HTP. The antiserum was also tested by pre-adsorption at 25 µg/mL with various BSA conjugates. While pre-adsorption with 5-HIAA conjugate completely eliminates immunolabeling, pre-adsorption with conjugates of 5-HT,5-HTP and dopamine had no effect on staining intensity or distribution of stain.
The Mu Opioid Receptor antiserum was quality control tested using standard immunohistochemical methods. The antiserum demonstrates strongly positive labeling of rat caudate putamen and spinal cord (dorsal horn) using indirect immunofluorescent and biotin/avidin-HRP techniques. Recommended primary dilutions are 1/500 - 1/1000 in PBS/0.3% Triton X-100 - Cy3 Technique and 1/6000 - 1/10000 in PBS/0.3% Triton X-100 - Biotin/avidin-HRP Technique. Preadsorption with MOR peptide (384-398) at 10 µg/ml completely eliminates labeling. The specificity of the antiserum was determined by immunolabeling of transfected cells, Western Blot analysis and immunoisolation studies.
The rabbit antibody for Glucagon-like Protein Receptor is generated for acetyl 65-88 amide sequence targeting rat and human proteins, but not mouse. The peptide was synthesized and cross-linked to keyhole limpet hemocyanin via sulfolink coupling. The antibody is provided as 100 µL of affinity purified serum containing 1% BSA.
Produced by Dr. Mark Brownfield, the peptide sequence encoding the rat GLP2R was retrieved from the NCBI protein database and evaluated using GeneRunner software to generate antigen candidates for antibody production. Antibody was generated in rabbits and purified by affinity chromatography against the antigenic peptide. The specificity of the antibody was confirmed by Western blotting and by immunoabsorption controls is the immunohistochemistry procedure (see Nelson et al, Endocrinology 148(5)1954-1962, 2007.
The antiserum demonstrates significant labeling of enteroendocrine cells in the intestinal epithelium, as well as cell bodies of vagal afferents in nodose ganglia of the parasympathetic nervous system. Immunolabeling of Western blot revealed a band of approximately 66 kDa in human and rat tissue.
Product Type:
Antibody - Antibodies
Antibody Type:
polyclonal
Format:
Liquid
Host Animal:
Rabbit
Species Reactivity:
Rat
Immunogen:
Glucagon-like peptide 2 receptor (GLP2R) for acetyl 65-88 amide sequence targeting rat and human proteins, but not mouse.
The rabbit antibody for Glucagon-like Protein Receptor is generated for acetyl 65-88 amide sequence targeting rat and human proteins, but not mouse. The peptide was synthesized and cross-linked to keyhole limpet hemocyanin via sulfolink coupling.
The CGRP Antibody was raised to rat alpha-CGRP coupled to bovine thyroglobulin with glutaraldehyde. The antibody has a proven fluorescein staining at a 1/100-1/200 dilution and a strong Biotin-Streptadvidin/HRP staining at a 1/2000-1/4000 dilution in rat amygdala, and spinal cord. The specificity of the antiserum was evaluated by soluble pre-adsorption with the peptides in question at a final concentration of 10-5M. CGRP immunolabeling was completely abolished by pre-adsorption with rat α -CGRP and partially eliminated by pre-adsorption with rat -CGRP. Pre-adsorption with the following peptides resulted in no loss of immunostaining: rat amylin, rat adrenomedulin, calcitonin, neurotensin, somatostatin, substance P, leucine enkephalin, methionine enkephalin, VIP, CCK-8, vasopressin and neuropeptide Y.
The Tyrosine Hydroxylase antiserum was quality control tested using standard immunohistochemical methods. The antiserum demonstrates strongly positive labeling of rat catecholamine neuron systems using indirect immunofluorescent and biotin/avidin-HRP techniques. Recommended primary dilutions for these methods are provided below. This antibody does not cross react with dihydropterdine reductase, dopamine-B-hydroxylase, phenylethanolamine-N-methyltransferase, phenylalanine hydroxylase or tryptophan hydroxylase using Western blot methods.
Neuropeptide Y (NPY) is a member of a regulatory peptide family and has a marked sequence homology with pancreatic polypeptide (PP) and peptide YY (PYY), which are other members of the family. In the rat central nervous system, immunohistochemistry has found NPY-like cell bodies in the cortex, caudate-putamen, hypothalamus (arcuate nucleus), hippocampus, anterior olfactory bulb, nucleus accumbens, amygdaloid complex and periaqueductal grey. NPY-like fibers and terminals are detected in high numbers in the bed nucleus of the stria terminalis, the peri- and paraventricular regions of the hypothalamus and thalamus and in discrete hypothalamic nuclei, particularly the suprachiasmatic nucleus. It has been used to detect NPY in a wide range of species including rat, mouse, human (1-7), fish, cat, bird, guinea pig, zebrafish, squirrels, frog, and newt.
Histamine is located in mast cells, endocrine cells of the gut, blood cells and in some cells of the peripheral and central nervous system. Histamine is a potent vasodilator when secreted by mast cells found in various tissues as a result of allergic hypersensitivity or inflammation. In the central nervous system, Histamine is putative neurotransmitter. In the brain, its highest content has been found in the hypothalamus and in certain areas of the mesencephalon. The Histamine antiserum has a sensitivity level capable of detecting the low level Histamine contents of the brain. The Histamine antiserum was quality control tested using standard immunohistochemical methods. The antiserum demonstrates strongly positive labeling of rat hypothalamus using indirect immunofluorescent and biotin/avidin-HRP techniques. Recommended primary dilutions are 1/500 - 1/1000 in PBS/0.3% Triton X-100 Cy3 Technique and 1/4000-1/6000 in PBS/0.3% Triton X-100 biotin/avidin-HRP Technique . All staining is blocked by preabsorption of the antiserum with Histamine conjugate. Cross reactivity experiments indicate no cross reactivity with L-histidine or L-histidine containing peptides such as LH-RH.
The GHRF (Growth Hormone Releasing Factor) Antibody was raised to rat hypothalamic GHRF (1-43). The antibody produces strong labeling of GHRH at dilutions of 1/200-1/400 using indirect immunofluorescence and at dilutions of 1/2,000 - 1/4,000 using biotin/streptavidin HRP in rat hypothalamus (median eminence). Cross reactivity of GHRF antiserum was examined using the paper spot technique of Larsson (1981). Using 2 µL, 100 pmole amounts, the following substances did not react with rat GHRF antisera diluted 1/500 using the PAP labeling method: glucagon, gastric inhibitory peptide, secretin, vasoactive intestinal peptide, peptide histidine isoleucine, pancreatic polypeptide (human or rat), human GHRF, somatostatin, insulin, ACTH, motilin, cholecystokinin octapeptide, substance P, molluscan cardioexcitatiory peptide, gastrin 34, and serotonin. GHRF antiserum had a very good reactivity using rat GHRF at 2 µL, 100 pmole amounts.
The antibody has a proven strong indirect immunofluorescence at 1/400 - 1/800 and 4+ biotin-streptavidin/HRP staining at a 1/2000 - 1/4000 dilution in rat brainstem, cerebellum and adrenal medulla. Using Western blot of purified DBH the antiserum detects a triplet at approximately 72-74 kD.
This antibody has been shown to react strongly with human GFAP as well as with GFAP from rat, mouse, guinea pig, hamster, kangaroo, sheep, cat and monkey. Excellent staining results were obtained when rabbit anti-glial fibrillary acidic protein serum was tested.
The gamma amino butyric acid antiserum was quality control tested using standard immunohistochemical methods. The antiserum demonstrates strongly positive labeling of rat thalamus and cerebellum using indirect immunofluorescent and biotin/avidin-HRP techniques. Recommended primary dilutions are 1/15,000- 1/20,000 in PBS /0.3% Triton X-100 - biotin/avidin-HRP technique. The specificity of the antiserum for GABA was evaluated using a competitive inhibition ELISA. While conjugates of GABA completely eliminate labeling, a 1000 fold excess of the following conjugates could not inhibit the antiserums ability to bind GABA conjugate: glutamate, aspartate, beta alanine, tyrosine, taurine, glycine and alanine.
The ImmunoStar gamma amino butyric acid antiserum was quality control tested using standard immunohistochemical methods. The antiserum demonstrates strongly positive labeling of rat thalamus and cerebellum using indirect immunofluorescent and biotin/avidin-HRP techniques. Recommended primary dilutions are 1/15,000- 1/20,000 in PBS /0.3% Triton X-100 - biotin/avidin-HRP technique. The specificity of the antiserum for GABA was evaluated using a competitive inhibition ELISA. While conjugates of GABA completely eliminate labeling, a 1000 fold excess of the following conjugates could not inhibit the antiserums ability to bind GABA conjugate: glutamate, aspartate, beta alanine, tyrosine, taurine, glycine and alanine.
The ImmunoStar VIAAT antiserum was quality control tested using standard immunohistochemical methods in rat brain and spinal cord using biotin/avidin-HRP techniques.Specificity of the antiserum was demonstrated by soluble pre-adsorption and Western blot. Tissue staining is completely eliminated by pretreatment of the diluted antibody with an excess of rat VIAAT peptide residues 511-525. Western blot analysis of immunoprecipitated rat brain homogenates demonstrates a dense immunoreactive band of approximately 57 kD and a minor band of approximately 36 kD.
The FMRF-Amide antiserum was quality control tested using standard histochemical methods. The antiserum demonstrates strongly positive labeling of rat hypothalamus and spinal cord using indirect immunofluorescent and biotin/avidin-HRP techniques. Recommended primary dilutions are 1/400 - 1/800 in PBS/0.3% Triton X-100 -Cy3 Technique and 1/1,000 - 1/2,000 in PBS/0.3% Triton X-100 - biotin/avidin-HRP Technique. Staining is completely eliminated by pretreatment of the diluted antibody with 100 µg/mL of FMRF-Amide.
The antibody has a proven strong immunofluorescent staining at a 1/200-1/400 dilution, and a 4+ Biotin-Streptavidin/HRP staining at a 1/500-1/1000 dilution, in rat adrenal medulla and rat stomach.
X
We use cookies to help personalise and improve your web experience.
By using our website you consent to our use of cookies, some of which may have already been set on your device.
View our Cookie Policy to learn more.
